Navigation Links
Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
Date:9/24/2008

REINACH, Switzerland, September 24 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced the completion of enrolment in the Phase II 'intravenous-to-oral' switch trial with oral iclaprim in patients with complicated Skin and Skin Structure Infections (cSSSI).

The trial was designed as a multi-centre, double-blind comparative study. Patients suffering from cSSSI received intravenous (IV) vancomycin for the first two days of treatment and were then randomised to either continue to receive IV vancomycin or to be switched to oral iclaprim for eight additional days. A total of 60 patients have been randomised for this study.

The key objective of the study is to assess the clinical efficacy of an oral capsule formulation of iclaprim as step-down therapy in comparison with IV vancomycin in the treatment of cSSSI. The primary endpoint is the clinical cure rate at the Test-of-Cure (TOC) visit. Secondary objectives include bacteriological outcome as well as safety and tolerability.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "The speed of enrolment in this Phase II trial surpassed our expectations. It again shows that an 'intravenous-to-oral' step-down therapy serves a medical need and could add significant value to intravenous iclaprim. Marketing applications for intravenous iclaprim have been filed in the U.S.A., the European Union and Canada. We will release the top-line data of this Phase II switch study in the coming months and subsequently determine the path ahead."

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company headquartered in Reinach, Switzerland with operations in Switzerland and the USA. It focuses on the discovery, development and commercialisation of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product can
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arpida Invited to Present Data on Iclaprim at Scientific Conference
2. Arpida Provides Further Comments on the Pivotal Phase III Trials
3. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... -- Report Details   Translational ... progress, and predicted revenues ,Where is the market for ... prospects for this market and related technologies? Visiongain,s brand ... to 2025, discussing data, opportunities and prospects. ... medicine : cell-based therapies that aim to restore function ...
(Date:2/27/2015)... Feb. 27, 2015  In recognition of Rare Disease ... the global bleeding disorders community, CSL Behring ... units (IUs) of protein therapies to the World Federation ... organization which has worked to improve the lives of ... donation supports the WFH,s Global Alliance for Progress (GAP) ...
(Date:2/27/2015)...  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the fourth quarter and full year ended December ... year for PTC. We are now a growing commercial-stage ... in the rare disease space," stated Stuart W. Peltz, ... proud to bring the first treatment for Duchenne muscular ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11
... McLaren Health Care and its Great,Lakes Cancer ... medical,minds to share the latest work underway around ... October 11th symposium, hosted by,McLaren and GLCI, was ... oncologist whose work in sentinel node mapping for,colorectal ...
... Changes Induced by ... in Patients with Celiac Disease, Additional Data Indicates Potential in ... Alba Therapeutics Corporation,presented results from two clinical studies this week ... Data from,study CLIN 1001-004, the first Phase IIa trial conducted ...
Cached Medicine Technology:News Media Advisory: World's Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6
(Date:2/27/2015)... patients die annually as a result of preventable medical harm—this ... each day. Now more than ever before, hospitals and patients ... they can to stay safe. , Through an exclusive ... discusses the importance of safer hospitals. “It’s incumbent upon all ... ensure that all our patients are in the safest environment ...
(Date:2/27/2015)... 27, 2015 Muscular Dystrophy Association ... Engineering at Duke University, recently announced a potentially ... young men with Duchenne muscular dystrophy (DMD). The ... and Gersbach will discuss their implications at MDA's ... in Washington, D.C. , Background: Gersbach and ...
(Date:2/27/2015)... 2015 Over 440,000 patients die each year ... now to educate readers on how they can take control ... serve as a guide to educate and inspire readers to ... loved ones safe with tips on topics ranging from hospital ... cover of the print publication. He recently spoke to ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 With cases of ... Dade area, concerned parents look to school administrations to help ... screenings. Though head lice is a common parasite that passes ... a nuisance, causing parents and teachers significant distress. , ... screenings at the school. This would allow parents and ...
(Date:2/27/2015)... Schenectady, New York (PRWEB) February 27, 2015 ... has been named one of the Best Companies to ... , “Transfinder recognizes the importance of creating a great ... a demanding – yet professionally fulfilling – environment. There’s ... doing great work together,” said Antonio Civitella, president and ...
Breaking Medicine News(10 mins):Health News:Dr. Richard Carmona, the 17th U.S. Surgeon General, and IntelliCentrics Raise Awareness in Mediaplanet’s “Patient Safety” Campaign 2Health News:Statement: New MDA-Funded Genetic Therapy Technique Targets DMD 2Health News:Safe and Sound: Improving Patient Outcomes through Mediaplanet’s “Patient Safety” Campaign 2Health News:South Florida Parents Put Pressure on Schools to Perform Lice Screenings to Prevent Spread of Lice According to One Miami Lice Removal Company Called Lice Troopers 2Health News:Transfinder Named a Best Company to Work for in New York State 2
... PLC (OTC,Bulletin Board: SNKTY), a Life Sciences company ... science of healthy aging, today announced,that its North ... an,amount up to $28 million to further advance ... including Invicorp(R)., Plethora Solutions Holdings PLC, a ...
... the POA, indicator reporting requirements by implementing data elements that expand, ... healthcare ... claims., ... their commitment for continuous improvement is,evident by assisting clients with compliance ...
... for future of loved ones with special ... ... Mutual,Life Insurance Company (MassMutual) today made available on its Web site a,free ... begin,developing or supplementing life care plans for family members with a,disability or ...
... ... With U.S. Presence, AMSTERDAM, The Netherlands, ... evolving field of cancer molecular diagnostics,today announced the appointment of Richard ... medical officer (CMO). Dr. Bender, who,will report directly to Chief Executive ...
... The U.S. Agency,for International Development (USAID) highlights ... the Agency,s community partnerships,in Africa as part of ... this,week. Admiral Timothy Ziemer, U.S. Malaria Coordinator, and ... join Jay Hein,Director of the White House Office ...
... the California NanoSystems Institute at UCLA have developed a novel ... inside tiny pores and release them into cancer cells in ... "nanoimpeller," the device is the first light-powered nanomachine that operates ... for cancer treatment. , UCLA researchers reported ...
Cached Medicine News:Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 2Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 3Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 4Health News:Data Dimensions Assists Clients With Compliance of 'Present on Admission' (POA) Indicator Reporting Requirements as Part of the April 1, 2008 Timeline 2Health News:MassMutual Offers Free 'Letter of Intent' Template to People with Disabilities and Their Families, Caregivers 2Health News:MassMutual Offers Free 'Letter of Intent' Template to People with Disabilities and Their Families, Caregivers 3Health News:Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer 2Health News:Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer 3Health News:USAID Participates in White House Office of Faith-Based and Community Initiatives Conferences in Rwanda and Zambia 2Health News:UCLA researchers design nanomachine that kills cancer cells 2Health News:UCLA researchers design nanomachine that kills cancer cells 3